(LGND) Ligand Pharmaceuticals - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US53220K5048
Stock: Vaccines, Antivirals, Oncology, CNS, Metabolic
Total Rating 65
Risk 84
Buy Signal -0.38
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.9% |
| Relative Tail Risk | -5.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.41 |
| Alpha | 47.19 |
| Character TTM | |
|---|---|
| Beta | 0.837 |
| Beta Downside | 0.791 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.51% |
| CAGR/Max DD | 1.05 |
Description: LGND Ligand Pharmaceuticals January 13, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) operates as a “virtual biotech,” discovering, developing, and then out-licensing a wide array of therapeutic assets across infectious disease, oncology, rare diseases, and specialty indications, while also commercializing a handful of marketed products such as VEKLURY (COVID-19) and VAXNEUVANCE (pneumococcal vaccine).
In FY 2023 the company generated roughly $1.2 billion in revenue, with licensing and royalty streams accounting for about 70 % of total sales, and it ended the year with a cash-plus-short-term-investments balance near $1.1 billion, giving it ample runway to fund its extensive pipeline.
Key macro drivers for Ligand include the growing demand for specialty and biologic therapies driven by an aging U.S. population, as well as a robust partnership ecosystem in biotech that rewards companies with strong IP and out-licensing capabilities; however, the firm remains sensitive to FDA approval timelines and the competitive landscape for its partnered assets.
For a deeper, data-driven valuation of LGND, you might explore the analytics platform at ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 48.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -4.07 > 1.0 |
| NWC/Revenue: 287.9% < 20% (prev 186.7%; Δ 101.2% < -1%) |
| CFO/TA 0.02 > 3% & CFO 31.9m > Net Income 48.6m |
| Net Debt (311.6m) to EBITDA (99.9m): 3.12 < 3 |
| Current Ratio: 24.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.2m) vs 12m ago 9.51% < -2% |
| Gross Margin: 85.90% > 18% (prev 0.94%; Δ 8497 % > 0.5%) |
| Asset Turnover: 20.66% > 50% (prev 15.96%; Δ 4.70% > 0%) |
| Interest Coverage Ratio: 17.28 > 6 (EBITDA TTM 99.9m / Interest Expense TTM 3.81m) |
Altman Z'' 6.03
| A: 0.49 (Total Current Assets 753.9m - Total Current Liabilities 30.5m) / Total Assets 1.48b |
| B: 0.39 (Retained Earnings 578.2m / Total Assets 1.48b) |
| C: 0.05 (EBIT TTM 65.9m / Avg Total Assets 1.22b) |
| D: 1.12 (Book Value of Equity 587.6m / Total Liabilities 526.6m) |
| Altman-Z'' Score: 6.03 = AAA |
Beneish M -2.76
| DSRI: 0.84 (Receivables 58.1m/42.1m, Revenue 251.2m/152.4m) |
| GMI: 1.09 (GM 85.90% / 93.50%) |
| AQI: 0.74 (AQ_t 0.48 / AQ_t-1 0.65) |
| SGI: 1.65 (Revenue 251.2m / 152.4m) |
| TATA: 0.01 (NI 48.6m - CFO 31.9m) / TA 1.48b) |
| Beneish M-Score: -2.76 (Cap -4..+1) = A |
What is the price of LGND shares?
As of February 02, 2026, the stock is trading at USD 192.10 with a total of 179,064 shares traded.
Over the past week, the price has changed by -4.50%, over one month by +1.00%, over three months by +2.69% and over the past year by +61.92%.
Over the past week, the price has changed by -4.50%, over one month by +1.00%, over three months by +2.69% and over the past year by +61.92%.
Is LGND a buy, sell or hold?
Ligand Pharmaceuticals has received a consensus analysts rating of 4.57.
Therefore, it is recommended to buy LGND.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LGND price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 243.4 | 26.7% |
| Analysts Target Price | 243.4 | 26.7% |
| ValueRay Target Price | 246.4 | 28.3% |
LGND Fundamental Data Overview January 26, 2026
P/E Trailing = 88.6123
P/E Forward = 24.2131
P/S = 15.7582
P/B = 4.1666
P/EG = 1.5271
Revenue TTM = 251.2m USD
EBIT TTM = 65.9m USD
EBITDA TTM = 99.9m USD
Long Term Debt = 445.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.18m USD (from shortTermDebt, last quarter)
Debt = 451.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 311.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.75b USD (3.96b + Debt 451.0m - CCE 664.5m)
Interest Coverage Ratio = 17.28 (Ebit TTM 65.9m / Interest Expense TTM 3.81m)
EV/FCF = 121.8x (Enterprise Value 3.75b / FCF TTM 30.8m)
FCF Yield = 0.82% (FCF TTM 30.8m / Enterprise Value 3.75b)
FCF Margin = 12.24% (FCF TTM 30.8m / Revenue TTM 251.2m)
Net Margin = 19.34% (Net Income TTM 48.6m / Revenue TTM 251.2m)
Gross Margin = 85.90% ((Revenue TTM 251.2m - Cost of Revenue TTM 35.4m) / Revenue TTM)
Gross Margin QoQ = 78.50% (prev 93.90%)
Tobins Q-Ratio = 2.54 (Enterprise Value 3.75b / Total Assets 1.48b)
Interest Expense / Debt = 0.20% (Interest Expense 910.0k / Debt 451.0m)
Taxrate = 16.91% (23.9m / 141.1m)
NOPAT = 54.7m (EBIT 65.9m * (1 - 16.91%))
Current Ratio = 24.69 (Total Current Assets 753.9m / Total Current Liabilities 30.5m)
Debt / Equity = 0.47 (Debt 451.0m / totalStockholderEquity, last quarter 950.2m)
Debt / EBITDA = 3.12 (Net Debt 311.6m / EBITDA 99.9m)
Debt / FCF = 10.13 (Net Debt 311.6m / FCF TTM 30.8m)
Total Stockholder Equity = 851.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.00% (Net Income 48.6m / Total Assets 1.48b)
RoE = 5.71% (Net Income TTM 48.6m / Total Stockholder Equity 851.2m)
RoCE = 5.08% (EBIT 65.9m / Capital Employed (Equity 851.2m + L.T.Debt 445.5m))
RoIC = 5.69% (NOPAT 54.7m / Invested Capital 962.5m)
WACC = 8.10% (E(3.96b)/V(4.41b) * Re(9.0%) + D(451.0m)/V(4.41b) * Rd(0.20%) * (1-Tc(0.17)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.82%
[DCF Debug] Terminal Value 77.02% ; FCFF base≈42.0m ; Y1≈40.0m ; Y5≈38.6m
Fair Price DCF = 18.29 (EV 671.6m - Net Debt 311.6m = Equity 360.0m / Shares 19.7m; r=8.10% [WACC]; 5y FCF grow -6.05% → 2.90% )
EPS Correlation: -11.27 | EPS CAGR: -36.20% | SUE: -2.17 | # QB: 0
Revenue Correlation: 19.09 | Revenue CAGR: 13.22% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.282 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=8.42 | Chg30d=+0.451 | Revisions Net=+5 | Growth EPS=+11.0% | Growth Revenue=+0.6%
P/E Forward = 24.2131
P/S = 15.7582
P/B = 4.1666
P/EG = 1.5271
Revenue TTM = 251.2m USD
EBIT TTM = 65.9m USD
EBITDA TTM = 99.9m USD
Long Term Debt = 445.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.18m USD (from shortTermDebt, last quarter)
Debt = 451.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 311.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.75b USD (3.96b + Debt 451.0m - CCE 664.5m)
Interest Coverage Ratio = 17.28 (Ebit TTM 65.9m / Interest Expense TTM 3.81m)
EV/FCF = 121.8x (Enterprise Value 3.75b / FCF TTM 30.8m)
FCF Yield = 0.82% (FCF TTM 30.8m / Enterprise Value 3.75b)
FCF Margin = 12.24% (FCF TTM 30.8m / Revenue TTM 251.2m)
Net Margin = 19.34% (Net Income TTM 48.6m / Revenue TTM 251.2m)
Gross Margin = 85.90% ((Revenue TTM 251.2m - Cost of Revenue TTM 35.4m) / Revenue TTM)
Gross Margin QoQ = 78.50% (prev 93.90%)
Tobins Q-Ratio = 2.54 (Enterprise Value 3.75b / Total Assets 1.48b)
Interest Expense / Debt = 0.20% (Interest Expense 910.0k / Debt 451.0m)
Taxrate = 16.91% (23.9m / 141.1m)
NOPAT = 54.7m (EBIT 65.9m * (1 - 16.91%))
Current Ratio = 24.69 (Total Current Assets 753.9m / Total Current Liabilities 30.5m)
Debt / Equity = 0.47 (Debt 451.0m / totalStockholderEquity, last quarter 950.2m)
Debt / EBITDA = 3.12 (Net Debt 311.6m / EBITDA 99.9m)
Debt / FCF = 10.13 (Net Debt 311.6m / FCF TTM 30.8m)
Total Stockholder Equity = 851.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.00% (Net Income 48.6m / Total Assets 1.48b)
RoE = 5.71% (Net Income TTM 48.6m / Total Stockholder Equity 851.2m)
RoCE = 5.08% (EBIT 65.9m / Capital Employed (Equity 851.2m + L.T.Debt 445.5m))
RoIC = 5.69% (NOPAT 54.7m / Invested Capital 962.5m)
WACC = 8.10% (E(3.96b)/V(4.41b) * Re(9.0%) + D(451.0m)/V(4.41b) * Rd(0.20%) * (1-Tc(0.17)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.82%
[DCF Debug] Terminal Value 77.02% ; FCFF base≈42.0m ; Y1≈40.0m ; Y5≈38.6m
Fair Price DCF = 18.29 (EV 671.6m - Net Debt 311.6m = Equity 360.0m / Shares 19.7m; r=8.10% [WACC]; 5y FCF grow -6.05% → 2.90% )
EPS Correlation: -11.27 | EPS CAGR: -36.20% | SUE: -2.17 | # QB: 0
Revenue Correlation: 19.09 | Revenue CAGR: 13.22% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.282 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=8.42 | Chg30d=+0.451 | Revisions Net=+5 | Growth EPS=+11.0% | Growth Revenue=+0.6%